Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ajay Goel PhD, AGAF

Ajay Goel PhD, AGAF

Professor and Chair, Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope; Associate Director of Basic Sciences, City of Hope Comprehensive Cancer Center; Professor, Irell and Manella Graduate School of Biological Sciences of City of Hope; Director, Biotech Innovations, City of Hope Medical Center, Duarte, California

Ajay Goel, PhD, AGAF, is a Professor and Founding Chair of the Department of Molecular Diagnostics at the Beckman Research Institute, as well as Associate Director of Basic Sciences at the City of Hope Comprehensive Cancer Center and also serves as Director of Biotech Innovations at the City of Hope, Duarte, CA.

Dr. Goel has spent over 25 years researching cancer and has been the lead author or contributor to over 425 scientific articles published in peer-reviewed international journals and several book chapters. He is also a primary inventor of over 75 international patents to develop various disease biomarkers or therapeutic targets for gastrointestinal cancers. He uses advanced genomic, epigenomic, and transcriptomic approaches to develop novel circulating, liquid biopsy-based biomarkers (e.g., cell-free nucleic acids, exosomes) for early detection, prognosis, and determining predictive responses to chemotherapy and targeted drugs in gastrointestinal cancers. In addition, his group is very interested in identifying novel therapeutic targets, particularly immune therapy, for various gastrointestinal cancers. His research also involves understanding the role of the gut microbiome, health disparities, and the prevention of gastrointestinal cancers using integrative and alternative approaches.

Dr. Goel is a member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Gastroenterology Association (AGA). He serves as the Editor-in-Chief, Senior editor, or as an editorial board member of more than 25 international journals, including Gastroenterology, Clinical Cancer Research, Carcinogenesis, Molecular Cancer Therapeutics, PLoS ONE, Molecular Carcinogenesis, Scientific Reports, Epigenomics, Future Medicine, Alternative Therapies in Health and Medicine, Digestive Diseases and Sciences and Molecular Therapy Oncolytics. He is also actively involved in peer-reviewing activities for more than 100 international scientific journals and various grant review panels of national and international funding organizations. 

His research has been actively funded for more than 20 years by various private and federal organizations, including funding from the National Cancer Institute (NCI) at the National Institutes of Health (NIH), the American Cancer Society (ACS), and many research foundations and other state organizations. He has won more than 50 national and international awards and honors and has been invited for visiting professorships by various national and international academic institutions and academic bodies. 


Dr. Goel has no relevant disclosures.